Taken together, these results suggest that inhibiting evf‐2 expression in kidney podocytes could represent an effective approach to alleviate podocyte injury, inflammation, and albuminuria associated with DN. This evidence concerns the gene DLX6-AS1 and liver dysplastic nodule.